Blue Gold Names Sameer Salgar of Quazar to Advisory Board to Strengthen UAE Connections and Shape Digital Gold Strategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 10 2025
0mins
Source: Newsfilter
Appointment of Advisory Board Member: Blue Gold Limited has appointed Sameer Salgar, CFO of Quazar Investment, to its Advisory Board, enhancing its strategic direction and acquisition strategy in the gold sector.
Focus on Digital Gold Initiative: Salgar will guide the rollout of digital technology solutions and assist in establishing UAE-based gold deposit infrastructure, aiming to strengthen Blue Gold's access to capital and expand its digital gold platform.
Analyst Views on NTHI
About NTHI
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
